Skin Microbiome Can Be Negatively Altered by Topical Antibiotics

        Scientists at the Perelman School of Medicine at the University of Pennsylvania say the use of topical antibiotics can dramatically alter communities of bacteria that live on the skin, while the use of antiseptics has a much smaller, less durable impact. The study (“Topical antimicrobial treatments can elicit shifts to resident skin bacterial communities and reduce colonization by Staphylococcus aureus competitors”), published in Antimicrobial Agents and Chemotherapy, was conducted in mice in the laboratory of Elizabeth Grice, Ph.D., an assistant professor of dermatology, and reportedly is the first to show the long-term effects of antimicrobial drugs on the skin microbiome.
Medicilon can undertake the development of various topical skin preparations, including ointments, creams, gels and other semi-solid preparations, as well as lotions, liniments and other solutions. Medicilon fully complies with the requirements of global laws, regulations and guiding principles, and can bring many years of R&D experience to support your projects. Medicilon has completed the development and application of a number of external preparation research projects for pharmaceutical companies and scientific research institutes.

        In the gut, research shows medication that alters microbial communities can lead to complications like Clostridium difficile, which causes diarrhea and is the most common hospital-acquired infection. But when it comes to the skin, the impact of these medications on bacteria strains like S. aureus, the most common cause of skin infections, is still largely unstudied.

        “We know antibiotics and antiseptics can be effective in stopping the growth of certain bacteria, but we wanted to know about the larger impact these treatments can have on the resident microbial communities on the skin,” said the study’s lead author, Adam J. SanMiguel, Ph.D., a researcher in the Grice Laboratory.

        Researchers treated the skin of hairless mice with a variety of antibiotics, including a narrowly targeted mupirocin ointment and a broadly applicable triple-antibiotic ointment (TAO) containing bacitracin, neomycin, and polymyxin B. All of the antibiotics changed the makeup of the microbial communities, and, in a key finding of the study, the impact of that change lasted for days after treatment stopped.

        “The problem in this case isn’t antibiotic resistance, but instead, how long the disruption of the skin microbiomes continues,” Dr. SanMiguel said. “That disruption opens the door for colonization by an unwanted strain.”

        The investigators similarly evaluated antiseptics, using alcohol or povidone-iodine and comparing those treatments with two control groups—mice treated with water and mice entirely untreated. They found neither antiseptic caused responses similar enough to cluster the mice together into groups based on their microbiomes. They also found no clear difference between the treatment groups and the control groups when comparing the relative number of individual bacteria strains.

        “We thought antiseptics would be even more disruptive to microbial communities than antibiotics since they are less targeted, but it turns out the opposite is true,” according to Dr. SanMiguel. “It shows how stable the skin microbiome can be in the face of stress.”

        However, both antibiotic and antiseptic treatments removed skin resident bacteria that compete against the pathogenic S. aureus to colonize the skin. Colonization with S. aureus is a risk factor for developing a skin infection.

        “This gives us a better understanding of how topical antimicrobials affect the skin microbiome and what kind of impact their disturbance can have in the context of pathogenic colonization,” explained Dr. Grice, the study’s senior author. “This helps us anticipate their potential effects.”

    The researchers say this work can provide the foundation for greater understanding of how the skin defends against infection. They have already begun similar testing in humans.